Get the Stockscreener App
3.01
0.66%
-0.02
After Hours:
3.05
0.04
+1.33%
Macrogenics Inc Stock (MGNX) Latest News
JPMorgan Chase & Co. Reduces Stock Position in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
MacroGenics Shares Tumble After Reporting Adverse Events, Multiple Deaths In Cancer Drug Trial - MSN
Barclays PLC Acquires 48,639 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Macrogenics Stock Hits 52-Week Low at $2.95 Amid Market Challenges - MSN
Macrogenics Stock Hits 52-Week Low at $2.95 Amid Market Challenges By Investing.com - Investing.com South Africa
JMP Securities Downgrades MacroGenics (MGNX) - MSN
Immunotoxins Market Trends and Regional Business Opportunities, 2024-2034: Diphtheria Toxin-Based Immunotoxins Lead Revenue, Pseudomonas Exotoxins Show Rapid Growth Potential - GlobeNewswire Inc.
MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.63 Average PT from Brokerages - MarketBeat
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of “Hold” by Analysts - Defense World
Geode Capital Management LLC Sells 8,363 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Shareholders that lost money on MacroGenics, Inc.(MGNX) Urged to - GuruFocus.com
Barclays PLC Has $325,000 Stake in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus.com
Stifel Financial Corp Purchases 6,578 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
State Street Corp Has $4.70 Million Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Shares Acquired by Fmr LLC - Defense World
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Victoria Advocate
Faruqi & Faruqi Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - The Eastern Progress Online
MacroGenics, Inc. (NASDAQ:MGNX) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Analysts Set MacroGenics, Inc. (NASDAQ:MGNX) PT at $7.63 - MarketBeat
MacroGenics' SWOT analysis: oncology firm faces pipeline challenges, stock outlook mixed - Investing.com Australia
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics - The Eastern Progress Online
Pharma Co. Brass Face Investor Suit Over Drug Trial Probe - Law360
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc.MGNX - The Eastern Progress Online
MacroGenics, Inc. Class Action: The Gross Law Firm Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - The Eastern Progress Online
Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your RightsMGNX - The Eastern Progress Online
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics - The Eastern Progress Online
MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
MacroGenics, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit - The Eastern Progress Online
Shareholders that lost money on MacroGenics, Inc.(MGNX) Urged to Join Class ActionContact The Gross Law Firm to Learn More - The Eastern Progress Online
Jacobs Levy Equity Management Inc. Purchases 147,438 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):